A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-03-23
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-05-16 (study day 42); relationship: not assessed
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-05-27 (study day 53); relationship: N
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-07-23 (study day 110); relationship: not assessed
moderate
assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-09-20 (study day 169); relationship: not assessed
Data queries
No data queries.